Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) EBIT Margin (2019 - 2025)

Historic EBIT Margin for Cyclerion Therapeutics (CYCN) over the last 6 years, with Q3 2025 value amounting to 114.97%.

  • Cyclerion Therapeutics' EBIT Margin rose 4664700.0% to 114.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 127.25%, marking a year-over-year increase of 29268700.0%. This contributed to the annual value of 181.4% for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Cyclerion Therapeutics' EBIT Margin stood at 114.97%, which was up 4664700.0% from 1797.85% recorded in Q2 2025.
  • Over the past 5 years, Cyclerion Therapeutics' EBIT Margin peaked at 27.8% during Q4 2024, and registered a low of 21604.84% during Q1 2021.
  • Over the past 4 years, Cyclerion Therapeutics' median EBIT Margin value was 1798.77% (recorded in 2025), while the average stood at 3505.29%.
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by -195743700bps in 2021, then skyrocketed by 197786800bps in 2022.
  • Quarter analysis of 4 years shows Cyclerion Therapeutics' EBIT Margin stood at 2690.06% in 2021, then tumbled by -63bps to 4389.87% in 2022, then skyrocketed by 101bps to 27.8% in 2024, then plummeted by -514bps to 114.97% in 2025.
  • Its EBIT Margin was 114.97% in Q3 2025, compared to 1797.85% in Q2 2025 and 1798.77% in Q1 2025.